The DF/HCC GI SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research into GI cancer. The overall goal of the CDP is to nurture the success of talented new researchers in GI cancer. By providing research support and exposure to the GI SPORE investigators, we hope to promote the independent research careers of junior faculty. Moreover, the SPORE CDP strives to attract minority and female investigators to the field of GI cancer. The investigators assembled in the DF/HCC GI SPORE have a substantial record in mentorship of junior faculty working in GI cancer research. The GI SPORE CDP has established a formal process for the identification, selection, and mentoring of individuals pursuing careers in the study of basic, clinical, and population science-based aspects of GI cancer. The CDP Governance and Review Committee, led by outstanding senior mentors across BWH, MGH, DFCI, and BIDMC, direct a program that ensures optimal selection, support, and oversight of the GI SPORE CDP. Over the past funding cycle, the CDP has selected, funded, and mentored 15 talented young investigators in GI cancer who have made exceptional career development as well as substantial contributions to the field of GI cancer.
The Specific Aims of the Career Development Program are: 1. Establish a system to identify promising young investigators seeking to become independent investigators in GI cancer research. 2. Provide funding and resources and monitor awardee progress. 3. Promote a mentoring environment in the SPORE that will assist in the career development of CDP awardees as well as other junior faculty. 4. Train and develop the next generation of leaders in GI cancer translational investigation.
Career development of young faculty is vital to the continued progress in reducing the burden of GI cancer. The DF/HCC GI SPORE Career Development Program (CDP) is designed to provide the incentive and structure necessary to attract junior investigators in basic, translational and clinical research to focus on key issues in GI cancer.
|Russo, Mariangela; Siravegna, Giulia; Blaszkowsky, Lawrence S et al. (2016) Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov 6:147-53|
|Kugel, Sita; SebastiÃ¡n, Carlos; Fitamant, Julien et al. (2016) SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell 165:1401-15|
|Kim, Sun A; Inamura, Kentaro; Yamauchi, Mai et al. (2016) Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer 114:199-206|
|Delaney, Susan K; Hultner, Michael L; Jacob, Howard J et al. (2016) Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn 16:521-32|
|Mima, Kosuke; Cao, Yin; Chan, Andrew T et al. (2016) Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol 7:e200|
|Whitley, Melodi Javid; Cardona, Diana M; Lazarides, Alexander L et al. (2016) A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med 8:320ra4|
|Ahronian, Leanne G; Corcoran, Ryan B (2016) Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Mol Cell Oncol 3:e1048405|
|Saha, Supriya K; Zhu, Andrew X; Fuchs, Charles S et al. (2016) Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist 21:594-9|
|Ou, Wen-Bin; Lu, Minmin; Eilers, Grant et al. (2016) Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53. Br J Cancer 115:1253-1263|
|Lazarides, Alexander L; Whitley, Melodi J; Strasfeld, David B et al. (2016) A Fluorescence-Guided Laser Ablation System for Removal of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma. Theranostics 6:155-66|
Showing the most recent 10 out of 481 publications